These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

937 related items for PubMed ID: 24583566

  • 1. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY, Kim SH, Cho SJ, Chung YC, Jung IK, Kim CY, Kim DH, Lee DG, Lee YH, Lim WJ, Na YS, Shin SE, Woo JM, Yoon JS, Yoon BH, Ahn YM, Kim YS.
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG, Risperidone Long-Acting Trial Investigators (R-LAI).
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F, Schreiner A, Thomas P, Sherif T.
    Clin Drug Investig; 2012 Apr 01; 32(4):267-79. PubMed ID: 22339430
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan 01; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E.
    Int Clin Psychopharmacol; 2013 Jul 01; 28(4):164-70. PubMed ID: 23587986
    [Abstract] [Full Text] [Related]

  • 9. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.
    Llorca PM, Sacchetti E, Lloyd K, Kissling W, Medori R.
    Int J Clin Pharmacol Ther; 2008 Jan 01; 46(1):14-22. PubMed ID: 18218293
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M.
    J Clin Psychiatry; 2004 Aug 01; 65(8):1084-9. PubMed ID: 15323593
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E, Kouniakis F, Siurkute A, Schreiner A, Don L.
    Int Clin Psychopharmacol; 2010 May 01; 25(3):149-54. PubMed ID: 20305567
    [Abstract] [Full Text] [Related]

  • 12. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.
    Clin Schizophr Relat Psychoses; 2014 Jul 01; 8(2):101-9, 109A. PubMed ID: 23446197
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
    Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A.
    Eur Psychiatry; 2010 May 01; 25(4):220-9. PubMed ID: 19926263
    [Abstract] [Full Text] [Related]

  • 17. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP, Bossie CA, Lachaux B, Bouhours P, Zhu Y, Lasser R, Gharabawi GM.
    Int Clin Psychopharmacol; 2007 Jan 01; 22(1):51-5. PubMed ID: 17159460
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M.
    Int J Geriatr Psychiatry; 2004 Sep 01; 19(9):898-905. PubMed ID: 15352149
    [Abstract] [Full Text] [Related]

  • 19. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
    Arunpongpaisal S, Srisurapanont M, Kongsakon R, Kitiwattanagul K, Samanwongthai U.
    J Med Assoc Thai; 2010 Mar 01; 93(3):343-50. PubMed ID: 20420110
    [Abstract] [Full Text] [Related]

  • 20. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
    Gastpar M, Masiak M, Latif MA, Frazzingaro S, Medori R, Lombertie ER.
    J Psychopharmacol; 2005 Sep 01; 19(5 Suppl):32-8. PubMed ID: 16144784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.